182 related articles for article (PubMed ID: 37935260)
1. JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study.
Fischer M; Olbrich P; Hadjadj J; Aumann V; Bakhtiar S; Barlogis V; von Bismarck P; Bloomfield M; Booth C; Buddingh EP; Cagdas D; Castelle M; Chan AY; Chandrakasan S; Chetty K; Cougoul P; Crickx E; Dara J; Deyà-Martínez A; Farmand S; Formankova R; Gennery AR; Gonzalez-Granado LI; Hagin D; Hanitsch LG; Hanzlikovà J; Hauck F; Ivorra-Cortés J; Kisand K; Kiykim A; Körholz J; Leahy TR; van Montfrans J; Nademi Z; Nelken B; Parikh S; Plado S; Ramakers J; Redlich A; Rieux-Laucat F; Rivière JG; Rodina Y; Júnior PR; Salou S; Schuetz C; Shcherbina A; Slatter MA; Touzot F; Unal E; Lankester AC; Burns S; Seppänen MRJ; Neth O; Albert MH; Ehl S; Neven B; Speckmann C
J Allergy Clin Immunol; 2024 Jan; 153(1):275-286.e18. PubMed ID: 37935260
[TBL] [Abstract][Full Text] [Related]
2. Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations-10 Children and Review of the Literature.
Deyà-Martínez A; Rivière JG; Roxo-Junior P; Ramakers J; Bloomfield M; Guisado Hernandez P; Blanco Lobo P; Abu Jamra SR; Esteve-Sole A; Kanderova V; García-García A; Lopez-Corbeto M; Martinez Pomar N; Martín-Nalda A; Alsina L; Neth O; Olbrich P
J Clin Immunol; 2022 Jul; 42(5):1071-1082. PubMed ID: 35486339
[TBL] [Abstract][Full Text] [Related]
3. Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
Kayaoglu B; Kasap N; Yilmaz NS; Charbonnier LM; Geckin B; Akcay A; Eltan SB; Ozturk G; Ozen A; Karakoc-Aydiner E; Chatila TA; Gursel M; Baris S
J Clin Immunol; 2021 May; 41(4):769-779. PubMed ID: 33475942
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.
Lobo PB; Guisado-Hernández P; Villaoslada I; de Felipe B; Carreras C; Rodriguez H; Carazo-Gallego B; Méndez-Echevarria A; Lucena JM; Aljaro PO; Castro MJ; Noguera-Uclés JF; Milner JD; McCann K; Zimmerman O; Freeman AF; Lionakis MS; Holland SM; Neth O; Olbrich P
J Clin Immunol; 2022 Aug; 42(6):1193-1204. PubMed ID: 35507130
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase inhibitors ameliorate clinical symptoms in patients with STAT3 gain-of-function.
Kaneko S; Sakura F; Tanita K; Shimbo A; Nambu R; Yoshida M; Umetsu S; Inui A; Okada C; Tsumura M; Yamada M; Suzuki H; Kosaki K; Ohara O; Shimizu M; Morio T; Okada S; Kanegane H
Immunother Adv; 2023; 3(1):ltad027. PubMed ID: 38549698
[TBL] [Abstract][Full Text] [Related]
6. Recapitulating primary immunodeficiencies with expanded potential stem cells: Proof of concept with STAT1 gain of function.
Liu X; Chan VSF; Smith KGC; Ming C; Or CS; Tsui FTW; Gao B; Cook MC; Liu P; Lau CS; Li PH
J Allergy Clin Immunol; 2024 Apr; 153(4):1125-1139. PubMed ID: 38072195
[TBL] [Abstract][Full Text] [Related]
7. JAK/STAT defects and immune dysregulation, and guiding therapeutic choices.
Chaimowitz NS; Smith MR; Forbes Satter LR
Immunol Rev; 2024 Mar; 322(1):311-328. PubMed ID: 38306168
[TBL] [Abstract][Full Text] [Related]
8. Patients with STAT1 Gain-of-function Mutations Display Increased Apoptosis which is Reversed by the JAK Inhibitor Ruxolitinib.
Dotta L; Todaro F; Baronio M; Giacomelli M; Pinelli M; Giambarda M; Brognoli B; Greco S; Rota F; Cortesi M; Soresina A; Moratto D; Tomasi C; Ferraro RM; Giliani S; Badolato R
J Clin Immunol; 2024 Apr; 44(4):85. PubMed ID: 38578354
[TBL] [Abstract][Full Text] [Related]
9. Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.
Bloomfield M; Kanderová V; Paračková Z; Vrabcová P; Svatoň M; Froňková E; Fejtková M; Zachová R; Rataj M; Zentsová I; Milota T; Klocperk A; Kalina T; Šedivá A
J Clin Immunol; 2018 Jul; 38(5):589-601. PubMed ID: 29934865
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Gillard L; Pouchot J; Cohen-Aubart F; Koné-Paut I; Mouterde G; Michaud M; Reumaux H; Savey L; Belot A; Fautrel B; Mitrovic S
Rheumatology (Oxford); 2023 Apr; 62(4):1594-1604. PubMed ID: 35920788
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study.
Albert MH; Sirait T; Eikema DJ; Bakunina K; Wehr C; Suarez F; Fox ML; Mahlaoui N; Gennery AR; Lankester AC; Beier R; Bernardo ME; Bigley V; Lindemans CA; Burns SO; Carpenter B; Dybko J; Güngör T; Hauck F; Lum SH; Balashov D; Meisel R; Moshous D; Schulz A; Speckmann C; Slatter MA; Strahm B; Uckan-Cetinkaya D; Meyts I; Vallée TC; Wynn R; Neven B; Morris EC; Aiuti A; Maschan A; Aljurf M; Gedde-Dahl T; Gurman G; Bordon V; Kriván G; Locatelli F; Porta F; Valcárcel D; Beguin Y; Faraci M; Kröger N; Kulagin A; Shaw PJ; Veelken JH; Diaz de Heredia C; Fagioli F; Felber M; Gruhn B; Holter W; Rössig C; Sedlacek P; Apperley J; Ayas M; Bodova I; Choi G; Cornelissen JJ; Sirvent A; Khan A; Kupesiz A; Lenhoff S; Ozdogu H; von der Weid N; Rovira M; Schots R; Vinh DC
Blood; 2022 Oct; 140(14):1635-1649. PubMed ID: 35344580
[TBL] [Abstract][Full Text] [Related]
12. Clinical Relevance of Gain- and Loss-of-Function Germline Mutations in STAT1: A Systematic Review.
Zhang W; Chen X; Gao G; Xing S; Zhou L; Tang X; Zhao X; An Y
Front Immunol; 2021; 12():654406. PubMed ID: 33777053
[No Abstract] [Full Text] [Related]
13. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
Favoino E; Prete M; Catacchio G; Ruscitti P; Navarini L; Giacomelli R; Perosa F
Autoimmun Rev; 2021 Mar; 20(3):102750. PubMed ID: 33482338
[TBL] [Abstract][Full Text] [Related]
14. Case report: Myocarditis in congenital STAT1 gain-of function.
Staels F; Roosens W; Giovannozzi S; Moens L; Bogaert J; Iglesias-Herrero C; Gijsbers R; Bossuyt X; Frans G; Liston A; Humblet-Baron S; Meyts I; Van Aelst L; Schrijvers R
Front Immunol; 2023; 14():1095595. PubMed ID: 37020552
[TBL] [Abstract][Full Text] [Related]
15. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL
Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281
[TBL] [Abstract][Full Text] [Related]
16. Conditioning regimens for inborn errors of immunity: current perspectives and future strategies.
Nishimura A; Miyamoto S; Imai K; Morio T
Int J Hematol; 2022 Jul; 116(1):7-15. PubMed ID: 35675025
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations.
Leiding JW; Okada S; Hagin D; Abinun M; Shcherbina A; Balashov DN; Kim VHD; Ovadia A; Guthery SL; Pulsipher M; Lilic D; Devlin LA; Christie S; Depner M; Fuchs S; van Royen-Kerkhof A; Lindemans C; Petrovic A; Sullivan KE; Bunin N; Kilic SS; Arpaci F; Calle-Martin O; Martinez-Martinez L; Aldave JC; Kobayashi M; Ohkawa T; Imai K; Iguchi A; Roifman CM; Gennery AR; Slatter M; Ochs HD; Morio T; Torgerson TR;
J Allergy Clin Immunol; 2018 Feb; 141(2):704-717.e5. PubMed ID: 28601685
[TBL] [Abstract][Full Text] [Related]
18. JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences.
Ott N; Faletti L; Heeg M; Andreani V; Grimbacher B
J Clin Immunol; 2023 Aug; 43(6):1326-1359. PubMed ID: 37140667
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.
Albert MH; Slatter MA; Gennery AR; Güngör T; Bakunina K; Markovitch B; Hazelaar S; Sirait T; Courteille V; Aiuti A; Aleinikova OV; Balashov D; Bernardo ME; Bodova I; Bruno B; Cavazzana M; Chiesa R; Fischer A; Hauck F; Ifversen M; Kałwak K; Klein C; Kulagin A; Kupesiz A; Kuskonmaz B; Lindemans CA; Locatelli F; Lum SH; Maschan A; Meisel R; Moshous D; Porta F; Sauer MG; Sedlacek P; Schulz A; Suarez F; Vallée TC; Winiarski JH; Zecca M; Neven B; Veys P; Lankester AC
Blood; 2022 Mar; 139(13):2066-2079. PubMed ID: 35100336
[TBL] [Abstract][Full Text] [Related]
20. The Spectrum of Inborn Errors of Immunity in the United Arab Emirates: 5 Year Experience in a Tertiary Center.
Shendi HM; Al Kuwaiti AA; Al Dhaheri AD; Al-Hammadi S
Front Immunol; 2022; 13():837243. PubMed ID: 35173743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
